SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. Shin Nippon Biomedical Laboratories, Ltd. Stock
Equities
2395
JP3379950003
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,379 JPY | +1.85% |
|
-0.29% | -18.67% |
| Sales 2024 | 26.45B 168M | Sales 2025 * | 30.5B 193M | Capitalization | 56.37B 357M |
|---|---|---|---|---|---|
| Net income 2024 | 5.53B 35.07M | Net income 2025 * | 4.3B 27.26M | EV / Sales 2024 | 2.98 x |
| Net Debt 2024 | 15.58B 98.75M | Net Debt 2025 * | 22.77B 144M | EV / Sales 2025 * | 2.59 x |
| P/E ratio 2024 |
11.4
x | P/E ratio 2025 * |
13.1
x | Employees | 1,341 |
| Yield 2024 |
3.29% | Yield 2025 * |
3.69% | Free-Float | 46.34% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.99% | ||
| 1 week | -0.29% | ||
| Current month | +1.69% | ||
| 1 month | +0.44% | ||
| 3 months | -10.21% | ||
| 6 months | -16.71% | ||
| Current year | -18.67% |
1 week
1 354.00
1 423.00
1 month
1 286.001 423.00
Current year
1 286.001 996.00
1 year
1 286.002 465.00
3 years
809.003 225.00
5 years
411.003 225.00
10 years
300.003 225.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 81-08-31 |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 02-04-30 |
Terumasa Hirai
CMP | Compliance Officer | - | 84-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 81-08-31 |
Ichiro Nagata
BRD | Director/Board Member | 38 | 17-03-31 |
| Sales & Marketing | 64 | 02-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.51% | 19 M€ | +3.41% | - | |
| 0.08% | 15 M€ | +8.30% | ||
| 0.01% | 17 M€ | +18.02% | - | |
| 0.01% | 138,841 M€ | +16.21% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-17 | 1,379 | +1.85% | 31 800 |
| 24-06-17 | 1,354 | -2.94% | 144,300 |
| 24-06-14 | 1,395 | 0.00% | 153,000 |
| 24-06-13 | 1,395 | -0.92% | 148,700 |
| 24-06-12 | 1,408 | +1.96% | 117,500 |
Delayed Quote Japan Exchange, June 17, 2024 at 08:29 pm EDT
More quotes
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
Calendar
2024-07-30
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1,354
JPY
Average target price
2,800
JPY
Spread / Average Target
+106.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.67% | 369M | |
| +38.66% | 53.67B | |
| +33.67% | 38.86B | |
| -7.81% | 38.76B | |
| -10.77% | 27.27B | |
| +11.77% | 25.91B | |
| -17.82% | 20.29B | |
| +35.09% | 12.78B | |
| +29.17% | 12.18B | |
| -3.05% | 11.96B |
- Stock Market
- Equities
- 2395 Stock
